Royalty Pharma plc (RPRX) concluded trading on Wednesday at a closing price of $34.05, with 7.09 million shares of worth about $241.42 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 31.42% during that period and on June 11, 2025 the price saw a gain of about 1.40%. Currently the company’s common shares owned by public are about 425.59M shares, out of which, 332.24M shares are available for trading.
Stock saw a price change of 1.82% in past 5 days and over the past one month there was a price change of 2.10%. Year-to-date (YTD), RPRX shares are showing a performance of 33.48% which increased to 24.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $24.05 but also hit the highest price of $34.31 during that period. The average intraday trading volume for Royalty Pharma plc shares is 5.06 million. The stock is currently trading 2.60% above its 20-day simple moving average (SMA20), while that difference is up 4.45% for SMA50 and it goes to 14.18% higher than SMA200.
Royalty Pharma plc (NASDAQ: RPRX) currently have 425.59M outstanding shares and institutions hold larger chunk of about 77.25% of that.
The stock has a current market capitalization of $19.15B and its 3Y-monthly beta is at 0.48. PE ratio of stock for trailing 12 months is 13.89, while it has posted earnings per share of $2.45 in the same period. Its PEG reads 1.29 and has Quick Ratio of 1.56 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RPRX, volatility over the week remained 1.07% while standing at 1.42% over the month.
Stock’s fiscal year EPS is expected to rise by 6.93% while it is estimated to increase by 13.89% in next year. EPS is likely to grow at an annualized rate of 10.77% for next 5-years, compared to annual growth of -21.51% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Morgan Stanley on May 16, 2025 offering an Overweight rating for the stock and assigned a target price of $51 to it. Coverage by UBS stated Royalty Pharma plc (RPRX) stock as a Neutral in their note to investors on June 03, 2024, suggesting a price target of $28 for the stock. On June 14, 2022, UBS Resumed their recommendations, while on May 13, 2022, Scotiabank Initiated their ratings for the stock with a price target of $53. Stock get a Buy rating from Goldman on April 27, 2022.
